←Back to Expert Scholars
Translational Medicine / 转化医学Lung Oncogenic Fusions
Byung-Chul Cho
MD, PhD
🏢Yonsei Cancer Center🌐South Korea
Professor of Medical Oncology
78
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Byung-Chul Cho leads major Asian NSCLC trials including amivantamab and lazertinib studies. His work spans EGFR, ALK, ROS1 and uncommon fusion driver NSCLC. He is a globally recognized translational oncology leader in Korea.
Share:
🧪Research Fields 研究领域
Asian NSCLC trials
EGFR fusions
ALK/ROS1 inhibitors
Amivantamab
Targeted therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Byung-Chul Cho 的研究动态
Follow Byung-Chul Cho's research updates
留下邮箱，当我们发布与 Byung-Chul Cho（Yonsei Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment